The American Academy of Microbiology has elected Florian Krammer, PhD, Mount Sinai Professor in Vaccinology, and Gustavo Palacios, PhD, Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, along with 63 peers to its Class of 2023 fellows. Fellows of the American Academy of Microbiology, an honorary leadership group and a think tank within the American Society for Microbiology (ASM), are elected annually through a highly selective peer-review process based on their records of scientific achievement and original contributions that have advanced microbiology.
“Academy Fellowship represents a prestigious honor, and it is my pleasure to congratulate and welcome Dr. Florian Krammer and Dr. Gustavo Palacios to the 2023 Class. Fellows are an exceptional group of scientists whose contributions have moved the field forward and whose expertise serves science and society,” said Arturo Casadevall, MD, PhD, Chair of the Academy Governors.
“I am very proud of the contributions made by Drs. Krammer and Palacios to the field and their efforts have led to major advancements in microbiology at Mount Sinai,” said Peter Palese, PhD, Horace W. Goldsmith Professor and Chair of Microbiology at Icahn Mount Sinai. “Dr. Krammer’s work on the development of a universal influenza virus vaccine preventing influenza and a vaccine inducing mucosal immunity against COVID-19 when given intranasally are both in human trials, and Dr. Palacios is a world leader in understanding new and emerging viruses, which is a prerogative for preventing future pandemics.”
Among the 2023 fellows in the United States, 34 percent are women and 35 percent are from historically underrepresented ethnic groups. In addition, fellows hail from all around the globe. The Class of 2023 represents fellows from 11 different countries, including Argentina, Australia, Canada, China, France, Germany, India, Israel, Singapore, the UK, and the United States.
Learn about the 2023 Fellowship Class here.
The American Society for Microbiology is one of the largest professional societies dedicated to the life sciences and is composed of 30,000 scientists and health practitioners. ASM’s mission is to promote and advance the microbial sciences. ASM advances the microbial sciences through conferences, publications, certifications, and educational opportunities. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry, and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to diverse audiences.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the
eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.
Ranked No. 14 nationwide in National Institutes of Health funding and in the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 34 academic departments and 44 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, and gastrointestinal and liver diseases.
Icahn Mount Sinai offers highly competitive MD, PhD, and master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. In addition, more than 535 postdoctoral research fellows are in training within the Health System.
A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into health care products and services that benefit the public.
Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.
The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.
——————————————————-
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.
